Pancreatic cancer is a common malignant neoplasm of digestive system with a fairly poor prognosis, the diagnosis rate in its early stage is low, and in recent years its incidence rate has become more and more high. Surgical remove is the only radical means, whereas only 20% of patients can get the oppotunity of surgery when the diagnosis is confirmed. More unfortunately, the five-year overall survival rate after the surgery is as low as 15 - 20%. Therefore, it is of clinical significance to improve the survival rate and to prolong survival time. Comprehensive interventional therapy has many advantages, as the technique is safe and mini-invasive with satisfactory short-term efficacy. Nowadays, interventional therapy has become the hot point in the research of pancreatic cancer. This paper aims to make a review about the current situation and progress of interventional treatment for advanced pancreatic cancer.

Objective To investigate the expression of the preferentially expressed antigen of melanoma (PRAME) gene in acute myeloid leukemia (AML),and to evaluate its applicability in monitoring minimal residual disease (MRD).Methods Bone marrow specimens were collected from 63 cases of de-novo AML,while 34 samples from 11 patients were tracked for 28 months.The level of PRAME mRNA was measured by real time RT-PCR.Results The PRAME gene expressed in 52.4 ％ (33/63) of de-novo patients,and the positive rate was highest in M3 than that in other subtypes of AML.The expression of PRAME became negative after treatment and increased in the following months before morphology relapse.Conclusion The PRAME gene is highly expressed in AML and could be a useful marker to monitor MRD.